
Maximizing benefit from onabotulinumtoxinA in upper facial lines requires appropriate dosing, according to a review of dosing science and clinical outcomes. Standard doses (~20–24 U per area) achieve a median effect duration of ~4 months. Underdosing leads to shorter efficacy and lower satisfaction without improving safety, while emerging data suggest higher-than-approved doses could enhance outcomes without added risks, particularly in the glabella.
Like
Save
Share